AltruBio
3 known investors
AltruBio develops antibody-based therapeutics for immunological and inflammatory diseases, with clinical-stage candidates (ALTB-268 and ALTB-168) targeting conditions such as ulcerative colitis, psoriatic arthritis, psoriasis, and acute graft versus host disease. Its programs are in preclinical through Phase II development.
Investors · 3
Frequently asked questions
- What does AltruBio do?
- AltruBio develops antibody-based therapeutics for immunological and inflammatory diseases, with clinical-stage candidates (ALTB-268 and ALTB-168) targeting conditions such as ulcerative colitis, psoriatic arthritis, psoriasis, and acute graft versus host disease. Its programs are in preclinical through Phase II development.
- Who are AltruBio's investors?
- AltruBio's investors include aMoon, Delos Capital, RA Capital.